141,533 results match your criteria Rheumatoid Arthritis


Anti-hyperalgesia effect of nanchelating based nano particle, RAc1, can be mediated via liver hepcidin expression modulation during persistent inflammation.

Int Immunopharmacol 2019 Feb 15;69:337-346. Epub 2019 Feb 15.

Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:

Objective: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder accompanied with hyperalgesia, edema and pain. At least 30% of the patients failed to respond to the available treatments and medications, which yet have a lot of serious adverse effects on patients. So, using novel technologies to produce more efficient medications is needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2019.02.003DOI Listing
February 2019

Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug.

Biochem Pharmacol 2019 Feb 15. Epub 2019 Feb 15.

Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address:

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes swelling, bone erosion, and joint disorder. Patients with RA therefore suffer from pain and physiological disability, and have a decreased quality of life. During the progression of RA, many different types of cells and inflammatory factors influence each other with an important role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.02.020DOI Listing
February 2019

[Irisin as a new marker for the early diagnosis of low-traumatic fractures in rheumatoid arthritis.]

Klin Lab Diagn 2018 ;63(11):702-706

Volgograd State Medical University, 400131, Volgograd, Russian Federation.

The aim of this study was to study the relationship between serum irisin level and the presence of low-traumatic bone fractures in rheumatoid arthritis (RA) patients. We examined 170 people including 110 RA patients and 60 healthy individuals as comparison group. The serum irisin level was determined with solid-phase enzyme-linked immunosorbent assay using ELISA Irisin test system (BioVendor, cat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18821/0869-2084-2018-63-11-702-706DOI Listing
January 2018

Acute and sub-acute toxicity of aqueous extract of aerial parts of N. E. Brown in mice and rats.

Heliyon 2019 Jan 29;5(1):e01179. Epub 2019 Jan 29.

Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences College of Health Sciences, University of Ilorin, Kwara State, Nigeria.

N. E. Brown (Asclepiadaceae) is a cactus-like shaped shrub widely used in traditional medicine for the treatment of rheumatoid arthritis, diabetes, infertility and impotence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.heliyon.2019.e01179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356088PMC
January 2019

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis.

Osteoporos Sarcopenia 2018 Dec 1;4(4):128-133. Epub 2018 Dec 1.

Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.

Objectives: Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovium, progressive erosion of the articular cartilage, and joint destruction. RA also causes secondary osteoporosis and muscle wasting. We investigated the effects of ibandronate (IBN), a bisphosphonate; eldecalcitol (ELD), an active vitamin D3 derivative; and combination treatment with both agents on secondary osteoporosis and muscle wasting using adjuvant-induced arthritis rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.afos.2018.11.085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372828PMC
December 2018

A Case of Rhupus-reporting of a Rare Entity.

Indian Dermatol Online J 2019 Jan-Feb;10(1):58-60

Department of Dermatology, Armed Forces Medical College, Pune, Maharashtra, India.

Rhupus syndrome, a rare entity, is the co-existence of systemic lupus erythematosus (SLE) with rheumatoid arthritis (RA). It manifests as more RA and less SLE related damages. The duration of the disease is longer than typical RA or SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_55_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362750PMC
February 2019

Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis.

Cell Death Discov 2019 6;5:62. Epub 2019 Feb 6.

1Division of Experimental and Translational Genetics, Children's Mercy, Kansas City, MO 64108 USA.

Nicotinamide phosphoribosyltransferase (NAMPT) functions in NAD synthesis, apoptosis, and inflammation. Dysregulation of NAMPT has been associated with several inflammatory diseases, including rheumatoid arthritis (RA). The purpose of this study was to investigate NAMPT's role in arthritis using mouse and cellular models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41420-018-0134-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365567PMC
February 2019

LIFE QUALITY EVALUATION USING "TIME TRADE OFF" METHOD FOR RHEUMATOID HANDS.

Acta Ortop Bras 2018 ;26(6):374-378

Hand and Microsurgery Group, Institute of Orthopedics and Traumatology Medical School, Universidade de Sao Paulo, Hospital das Clinicas HCFMUSP, Sao Paulo, SP, Brazil.

Objective: Rheumatoid arthritis is a prevalent disease in the population (range 0.5% to 1%) and involves both orthopedic and rheumatologic treatment. The Time Trade-Off (TTO) technique, which determines the number of years the patient or the professional would be allowed before a successful procedure in terms of life expectancy and value of the procedure, has been gaining ground in clinical protocols. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1413-785220182606199308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362677PMC
January 2018

Sjögren's syndrome and systemic lupus erythematosus: links and risks.

Open Access Rheumatol 2019 29;11:33-45. Epub 2019 Jan 29.

Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil,

Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) may coexist, and they are chronic complex disorders, with an autoimmune background, multifactorial etiology, multiple circulating autoantibodies, and variable prognosis. The prominent feature of SS is the impairment of the lacrimal and salivary glands leading to sicca symptoms. This disease may be classified as primary Sjögren's syndrome (pSS), or secondary Sjögren's syndrome (sSS) since it is often associated to other autoimmune disorders, principally SLE, rheumatoid arthritis, and systemic sclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OARRR.S167783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357904PMC
January 2019

Comparison of health-related quality of life in patients with rheumatoid arthritis during conventional or conventional plus biological therapy in Poland.

Patient Prefer Adherence 2019 24;13:223-231. Epub 2019 Jan 24.

Department of Clinical Nursing Faculty of Health Sciences, Medical University, Wroclaw, Poland.

Purpose: The main purpose of this study was to compare the level of health-related quality of life (HRQoL) using Nottingham Health Profile (NHP) in Polish patients with rheumatoid arthritis (RA) during therapy applying disease-modifying antirheumatic drugs (DMARDs) with conventional synthetics (csDMARDs) or with csDMARDs in combination with biological drugs (bDMARDs). The second purpose was to analyze the correlation between the domain values of NHP and the demographic and clinical parameters, functional efficiency, and mood.

Patients And Methods: The studies involved 212 patients with RA, divided into two groups: group I - 126 persons treated using csDMARDs, group II - 86 patients using csDMARDs in combination with bDMARDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PPA.S189152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352871PMC
January 2019

Meloxicam in the management of post-operative pain: Narrative review.

J Anaesthesiol Clin Pharmacol 2018 Oct-Dec;34(4):450-457

Department of Anesthesiology, Rutgers-New Jersey Medical School, Newark, NJ, USA.

Oral formulations of meloxicam, a preferential cyclooxygenase-2 (COX-2) inhibitor, have long been used to treat osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, as well as various pain syndromes of skeletomuscular origin (e.g., low back pain). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/joacp.JOACP_133_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360894PMC
February 2019

Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach.

SAR QSAR Environ Res 2019 Feb 18:1-28. Epub 2019 Feb 18.

a Ion Channel Biology Laboratory, AU-KBC Research Centre, Madras Institute of Technology, Anna University , Chennai , India.

Upregulation of store-operated Ca influx via ORAI1, an integral component of the CRAC channel, is responsible for abnormal cytokine release in active rheumatoid arthritis, and therefore ORAI1 has been proposed as an attractive molecular target. In this study, we attempted to predict the mechanical insights of ORAI1 inhibitors through pharmacophore modelling, 3D-QSAR, molecular docking and free energy analysis. Various hypotheses of pharmacophores were generated and from that, a pharmacophore hypothesis with two hydrogen bond acceptors, one hydrogen bond donor and two aromatic rings (AADRR) resulted in a statistically significant 3D-QSAR model (r = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1062936X.2019.1566172DOI Listing
February 2019

Self-Nanoemulsifying Electrospun Fiber Enhancing Drug Permeation.

ACS Appl Mater Interfaces 2019 Feb 18. Epub 2019 Feb 18.

Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital , Shanghai Jiao Tong University School of Medicine , 197 Ruijin 2nd Road , Shanghai 200025 , P. R. China.

Electrospun fibers are excellent drug carriers and tissue engineering scaffolds. However, approaches to promote drug permeation in tissues with such carriers remain of great interest. Here, we propose a Quality-by-Design strategy to enhance drug permeation with self-nanoemulsifying electrospun fibers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.8b21967DOI Listing
February 2019

Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis.

Intern Med 2019 15;58(4):593-601. Epub 2019 Feb 15.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.

Rheumatoid vasculitis is a rare etiology for pulmonary hypertension (PH) in patients with connective tissue disease. We encountered a case of acute PH crisis in a case with rheumatoid vasculitis eight months after undergoing adalimumab reduction. Since no repetition of arthralgia occurred after the adalimumab reduction, we decided to not increase the dose of adalimumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.1143-18DOI Listing
February 2019

Development of a highly sensitive fluorescence probe for peptidyl arginine deiminase (PAD) activity.

Bioorg Med Chem Lett 2019 Jan 25. Epub 2019 Jan 25.

Graduate School of Pharmaceutical Science, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi, Japan. Electronic address:

Peptidyl arginine deiminases (PADs) catalyze the post-translational deimination of arginine residues to citrulline residues. Aberrant levels of PAD activity are associated with various diseases, such as rheumatoid arthritis, Alzheimer's disease, and multiple sclerosis, so there is a need for simple and convenient high-throughput screening systems to discover PAD inhibitors as candidate therapeutic agents. Here, we report a highly sensitive off/on-type fluorescence probe for PAD activity based on the donor-excited photoinduced electron transfer (d-PeT) mechanism, utilizing the specific cycloaddition reaction between the benzil group of the probe and the ureido group of the PAD product, citrulline, under acidic conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2019.01.032DOI Listing
January 2019

Clinical significance and immunobiology of IL-21 in autoimmunity.

J Autoimmun 2019 Feb 14. Epub 2019 Feb 14.

Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, PR China. Electronic address:

Interleukin-21 (IL-21), an autocrine cytokine predominantly produced by follicular helper T (Tfh) and T helper 17 (Th17) cells, has been proven to play an important role in the immune system, for example, by promoting proliferation and the development of Tfh and Th17 cells, balancing helper T cell subsets, inducing B cell generation and differentiation into plasma cells, and enhancing the production of immunoglobulin. These effects are mainly mediated by activation of the JAK/STAT, MAPK and PI3K pathways. Some IL-21 target genes, such as B lymphocyte induced maturation protein-1 (Blimp-1), suppressor of cytokine signaling (SOCS), CXCR5 and Bcl-6, play important roles in the immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2019.01.013DOI Listing
February 2019

Do recent research studies validate the medicinal plants used in British Columbia, Canada for immune-mediated and other problems in pets?

Authors:
Cheryl Lans

J Ethnopharmacol 2019 Feb 14. Epub 2019 Feb 14.

Institute for Ethnobotany and Zoopharmacognosy (IEZ) Rijksstraatweg 158A | 6573 DG | Beek | the Netherlands. Electronic address:

Ethnopharmacological Relevance: There are insufficient safe and effective treatments for chronic pain in pets. In cases such as osteoarthritis there is no commercially available cure and veterinarians use NSAIDs to manage pain. Pet owners may have to plan for a lifetime of plant-based treatment for the conditions that lead to chronic pain in pets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.02.030DOI Listing
February 2019

Bilateral Epibulbar Pseudorheumatoid Nodulosis with a Review of Ocular Adnexal Palisading Granulomas.

Surv Ophthalmol 2019 Feb 14. Epub 2019 Feb 14.

Cornea and Refractive Surgery Service; Massachusetts Eye and Ear Infirmary and the Harvard Medical School, Boston, MA.

We describe the clinical, histopathologic and immunohistochemical characteristics of episcleral/conjunctival pseudorheumatoid nodulosis, a new granulomatous entity that belongs among a group of related lesions. Specifically, pseudorheumatoid nodulosis should be differentiated from solitary rheumatoid nodules, rheumatoid nodulosis, accelerated rheumatoid nodules and nodulosis, and solitary pseudorheumatoid nodules. A 53-year-old man presented with bilateral painless, large, faintly yellow-grey, partially immobile, solid, circumscribed and occasionally confluent episcleral nodules of several months' duration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.survophthal.2019.02.002DOI Listing
February 2019

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.

Bioorg Med Chem 2019 Feb 6. Epub 2019 Feb 6.

Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan; Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8150, Japan. Electronic address:

The chemokine receptor CXCR4/stromal cell-derived factor-1 (SDF-1: CXCL12) signaling axis represents a crucial drug target due to its relevance to several diseases such as HIV-1 infection, cancer, leukemia, and rheumatoid arthritis. With the aim of enhancing the binding affinity and anti-HIV activity of a potent CXCR4 ligand as a lead, 23 low molecular weight compounds containing dipicolylamine (Dpa) and cyclam cationic moieties with varying spacers and spatial positioning were designed, synthesized and biologically evaluated. All of the synthesized compounds screened at 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2019.02.013DOI Listing
February 2019

Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.

Semin Arthritis Rheum 2019 Jan 25. Epub 2019 Jan 25.

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste-Catherine, H-461 Montreal, Québec H3T 1E2, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Québec, Canada. Electronic address:

Objective: To assess whether abatacept as initial biologic disease-modifying antirheumatic drug (DMARD) in the treatment of rheumatoid arthritis is associated with an increased risk of serious infections, including bone and joint, gastrointestinal, respiratory tract, skin and soft tissue, and urinary tract, when compared with other biologic DMARDs.

Methods: We performed a population-based cohort study among patients newly-treated with biologic DMARDs within the US-based Truven MarketScan® population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of serious infections requiring hospitalisation associated with initiation of abatacept, compared with initiation of other bDMARDs, after controlling for age and deciles of the propensity score. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.01.009DOI Listing
January 2019

Mediastinal, retroperitoneal, and subcutaneous emphysema due to sigmoid colon penetration: A case report and literature review.

Int J Surg Case Rep 2019 Feb 10;55:213-217. Epub 2019 Feb 10.

Department of Acute Care Surgery, Shimane University, Faculty of Medicine, Shimane, Japan.

Introduction: Mediastinal and subcutaneous emphysema usually result from spontaneous rupture of the alveolar wall. We present an extremely rare case of massive mediastinal, retroperitoneal, and subcutaneous emphysema due to the penetration of the colon into the mesentery.

Presentation Of Case: A 57-year-old man presented to our institution with a history of chest pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.02.003DOI Listing
February 2019
1 Read

Development and validation of an F-FDG PET/CT-based tool for the evaluation of joint counts and disease activity in patients with rheumatoid arthritis.

Arthritis Rheumatol 2019 Feb 16. Epub 2019 Feb 16.

Department of Internal Medicine, School of Medicine, Kyungpook National University, Korea.

Objectives: Clinical joint count assessment is important for detecting synovitis but its reliability is controversial. This study assessed the correlation of positron emission tomography (PET)-derived parameters in 68 joints with disease activity and compared the reliability of joint counts between PET/computed tomography (CT) and clinical assessment in rheumatoid arthritis (RA).

Methods: We enrolled 91 patients with active RA who underwent fluorine-18-fluorodeoxyglucose PET/CT and disease activity evaluation at the same time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40860DOI Listing
February 2019

Regulatory effects of paeoniflorin-6'-O-benzene sulfonate (CP-25) on dendritic cells maturation and activation via PGE2-EP4 signaling in adjuvant-induced arthritic rats.

Inflammopharmacology 2019 Feb 15. Epub 2019 Feb 15.

Institute of Clinical Pharmacology, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. Dendritic cells (DCs) are one of the most powerful antigen-presenting cells, and they play an important role in RA pathogenesis. Prostaglandin E2 (PGE2) is a potent lipid mediator that can regulate the maturation and activation of DCs, but the molecular mechanisms have not been elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10787-019-00575-8DOI Listing
February 2019

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.

Arthritis Res Ther 2019 Feb 15;21(1):61. Epub 2019 Feb 15.

Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.

Background: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and the involvement of multiple internal organs. Previous studies reported poorer health-related quality of life (HRQoL) in patients with SSc compared with the general population. However, very little is known about how HRQoL in SSc patients compares with that in patients with other systemic autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjogren's syndrome (SjS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1842-xDOI Listing
February 2019

Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients-immune-related candidate proteins affected by TNF blocking treatment.

Arthritis Res Ther 2019 Feb 15;21(1):60. Epub 2019 Feb 15.

Rheumatology Unit, Department of Medicine, Solna, Center of Molecular Medicine (CMM), Karolinska Institutet, Karolinska University Hospital, SE-17176, Stockholm, Sweden.

Background: Signs of inflammation in cerebrospinal fluid (CSF) of rheumatoid arthritis patients correlate positively with fatigue, a central nervous system (CNS)-related symptom that can be partially suppressed by TNF blockade. This suggests a possible role for CNS inflammation in arthritis that may be affected by TNF blockade. We therefore investigated the effects of TNF blockade on the arthritis CSF proteome and how candidate proteins related to clinical measures of disease activity and inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1846-6DOI Listing
February 2019

Rates and outcomes of total knee replacement for rheumatoid arthritis compared to osteoarthritis.

ANZ J Surg 2019 Feb 15. Epub 2019 Feb 15.

South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.

Background: Total knee replacement (TKR) has been shown to perform differently in patients with rheumatoid arthritis (RA) when compared to osteoarthritis (OA). In this study, we compare the survivorship between these two groups and examine patient and prosthesis factors that impact the revision rate.

Methods: All RA and OA patients undergoing TKR in Australia from 1 September 1999 to 31 December 2016 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.15035DOI Listing
February 2019

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From the CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, UK; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Epidemiology and Biostatistics; Amsterdam Rheumatology and Immunology Center; Amsterdam University Medical Centers, location VUmc, Amsterdam, the Netherlands; Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College; Pfizer, New York, New York; Sanofi, Bridgewater, New Jersey; SDG LLC, Cambridge, Massachusetts, USA; Rebecca McDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Division of Rheumatology, Department of Medicine and Therapeutics, and Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. EHC has received research grants and/or served as a member of advisory boards and speaker bureaus of Pfizer and Sanofi. HvH is an employee of Sanofi-Genzyme and holds stock in the company. LST has received research grants and/or served as a member of advisory boards and speaker bureaus of AbbVie, Eli Lilly, Celltrion, Janssen, Novartis, Pfizer, Roche, and Sanofi. JC is an employee of Pfizer. T. Pickles, MSc, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University; R. Alten, MD, PhD, Schlosspark Klinik, Charité University Medicine; M. Boers, MD, PhD, MSc, Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, and Amsterdam University Medical Centers VUmc; V. Bykerk, MD, FRCPC, Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, and Rebecca McDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, University of Toronto; J. Christensen, MD, Pfizer; R. Christensen, PhD, MSc, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, and Department of Rheumatology, Odense University Hospital; H. van Hoogstraten, MD, PhD, Sanofi; L.S. Simon, MD, SDG LLC; L.S. Tam, MD, Division of Rheumatology, Department of Medicine and Therapeutics, and Faculty of Medicine, The Chinese University of Hong Kong; E.H. Choy, MD, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University. Address correspondence to Professor E.H. Choy, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff University, Cardiff, UK CF14 4XN. E-mail: Accepted for publication December 18, 2018.

Objective: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.

Methods: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181054DOI Listing
February 2019

Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS).

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From the Department of Rheumatology, Diakonhjemmet Hospital; Institute of Health and Society, University of Oslo, Oslo, Norway; Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen; King Christian 10th Hospital for Rheumatic Diseases; University of Southern Denmark, Institute of Regional Health Research, Graasten; Institute of Clinical Medicine, Aarhus University Hospital, Århus; Odense University Hospital; Institute of Clinical Research, University of Southern Denmark, Odense; Zealand University Hospital, Køge, Denmark; University of New South Wales, Sydney, Australia; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. U. Sundin, MD, Research Fellow, Department of Rheumatology, Diakonhjemmet Hospital, and Institute of Health and Society, University of Oslo; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen; D. Glinatsi, MD, PhD, Postdoctoral Researcher, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet; A.B. Aga, MD, PhD, Senior Consultant and Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital Oslo; K. Hørslev-Petersen, MD, DMSc, Professor, Senior Consultant, King Christian 10th Hospital for Rheumatic Diseases, and the Institute of Regional Health Research, University of Southern Denmark; M.L. Hetland, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen; K. Stengaard-Pedersen, MD, DMSc, Professor Emeritus, Institute of Clinical Medicine, Aarhus University Hospital; P. Junker, MD, DMSc, Professor, Department of Rheumatology, Odense University Hospital and Institute of Clinical Research, University of Southern Denmark; B.J. Ejbjerg, MD, PhD, Chief Consultant, Zealand University Hospital; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of New South Wales; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre; S. Lillegraven, MD, MPH, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; E.A. Haavardsholm, MD, PhD, Professor, Department of Rheumatology, Diakonhjemmet Hospital, and Institute of Health and Society, University of Oslo. Address correspondence to Dr. U. Sundin, Diakonhjemmet Sykehus, Diakonveien 12, 0370 Oslo, Norway. E-mail: Accepted for publication December 6, 2018.

Objective: The RAMRIS [Outcome Measures in Rheumatology rheumatoid arthritis (RA) magnetic resonance imaging (MRI) Scoring system] is used in clinical RA trials. We have investigated methods to combine the RAMRIS features into valid and responsive scores for inflammation and joint damage.

Methods: We used data from 3 large randomized early RA trials to assess 5 methods to develop a combined score for inflammation based on RAMRIS bone marrow edema, synovitis, and tenosynovitis scores, and a combined joint damage score based on erosions and joint space narrowing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181064DOI Listing
February 2019

Structural Changes over a Short Period Are Associated with Functional Assessments in Rheumatoid Arthritis.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From the Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, and the Department of Medicine, Division of Rheumatology, and the School of Pharmacy, at the University of California, San Francisco (UCSF), San Francisco, California; Department of Biomedical Engineering, Program of Advanced Musculoskeletal Imaging (PAMI), Cleveland Clinic, Cleveland, Ohio; Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. This study was supported by UCB Pharmaceutical Inc. (Xiaojuan Li). T. Shimizu, MD, PhD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, and Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University; A. Cruz, BS, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, and School of Pharmacy, UCSF; M. Tanaka, BS, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF; K. Mamoto, MD, PhD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, and Department of Biomedical Engineering, PAMI, Cleveland Clinic; V. Pedoia, PhD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF; A.J. Burghardt, BS, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF; U. Heilmeier, MD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF; T.M. Link, MD, PhD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF; J. Graf, MD, Department of Medicine, Division of Rheumatology, UCSF; J.B. Imboden, MD, Department of Medicine, Division of Rheumatology, UCSF; X. Li, PhD, Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, and Department of Biomedical Engineering, PAMI, Cleveland Clinic. Address correspondence to Dr. T. Shimizu, Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. E-mail: Accepted for publication October 24, 2018.

Objective: To investigate the correlation between changes in radiological quantitative assessment with changes in clinical and functional assessment from baseline to 3 months in patients with rheumatoid arthritis (RA).

Methods: Twenty-eight patients with RA [methotrexate (MTX) and anti-tumor necrosis factor-α (TNF-α) group with high disease activity (n = 18); and MTX group with low disease activity (n = 10)] underwent assessments at baseline and 3 months: clinical [28-joint count Disease Activity Score (DAS28)], functional [Health Assessment Questionnaire (HAQ) and Michigan Hand Outcome Questionnaire (MHQ)], and imaging-based [3 Tesla magnetic resonance imaging (MRI) and high-resolution peripheral quantitative computed tomography (HR-pQCT)]. MR images were evaluated semiquantitatively [RA MRI scoring (RAMRIS)] and quantitatively for the volume of synovitis and bone marrow edema (BME) lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180496DOI Listing
February 2019

Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease.

Int J Mol Sci 2019 Feb 15;20(4). Epub 2019 Feb 15.

Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131 Naples, Italy.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inteleukin-3 (IL-3) have long been known as mediators of emergency myelopoiesis, but recent evidence has highlighted their critical role in modulating innate immune effector functions in mice and humans. This new wealth of knowledge has uncovered novel aspects of the pathogenesis of a range of disorders, including infectious, neoplastic, autoimmune, allergic and cardiovascular diseases. Consequently, GM-CSF and IL-3 are now being investigated as therapeutic targets for some of these disorders, and some phase I/II clinical trials are already showing promising results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040834DOI Listing
February 2019

IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review.

Medicina (Kaunas) 2019 Feb 14;55(2). Epub 2019 Feb 14.

School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125 Messina, Italy.

Interleukin-33 (IL-33) is a cytokine belonging to the IL-1 family, playing a role in inflammatory, infectious and autoimmune diseases and expressed in the cellular nucleus in several tissues. High levels of IL-33 are expressed in epithelial barrier tissues and endothelial barriers. ST2 is a receptor for IL-33, expressed selectively on a subset of Th2 cells, mediating some of their functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina55020050DOI Listing
February 2019

MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB Signaling.

Int J Mol Sci 2019 Feb 14;20(4). Epub 2019 Feb 14.

Institute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba 279-0021, Japan.

MicroRNA (miRNA) is small RNA of 20 to 22 nucleotides in length and is stably present in plasma. Regulating the expression of miRNA taken into cells has been suggested as a general therapeutic approach. We identified the novel anti-inflammatory miRNA hsa-miR-766-3p and investigated its biological function in human rheumatoid arthritis (RA) fibroblast-like synoviocyte MH7A cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040809DOI Listing
February 2019

Aleurites moluccanus and its main active constituent, the flavonoid 2''-O-rhamnosylswertisin, in experimental model of rheumatoid arthritis.

J Ethnopharmacol 2019 Feb 12. Epub 2019 Feb 12.

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil; Pharmacy Course, Universidade do Vale do Itajaí (UNIVALI), Itajaí, Santa Catarina, Brazil.

Ethnopharmmacological Relevance: Aleurites moluccana is used in folk medicine to treat pain, fever, asthma, hepatitis, gastric ulcer and inflammatory process in general, and the nut oil had been topically applied to treat arthritis and other joint pain, however the seeds are classified as toxic for oral use.

Aim: Faced with the need for new alternative to treat the symptoms and modify rheumatoid arthritis (RA) the aim of this work was to evaluate the effects of A. moluccanus' leaves dried extract in rats and mice submitted to complete Freund adjuvant (CFA)-induced RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.02.014DOI Listing
February 2019

IgMCD27 B cells possessed regulatory function and represented the main source of B cell-derived IL-10 in the synovial fluid of osteoarthritis patients.

Hum Immunol 2019 Feb 12. Epub 2019 Feb 12.

Department of Orthopedics, Shandong Qianfoshan Hospital, Shandong University, Jinan, Shandong, China. Electronic address:

Synovial inflammation is observed in patients with osteoathritis (OA) and likely contributed to its exacerbation. Regulatory B (Breg) cells are shown to suppress inflammation in various diseases, including rheumatoid arthritis (RA). To examine whether Breg cells also participated in OA, we examined the synovial fluid from OA patients, and compared with that in RA patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2019.02.007DOI Listing
February 2019

Patient Perspectives on Smoking Cessation and Interventions in Rheumatology Clinics.

Arthritis Care Res (Hoboken) 2019 Feb 15. Epub 2019 Feb 15.

UW-SMPH Department of Medicine, Rheumatology, Madison, WI, United States.

Objective: Although smoking is a risk factor for cardiovascular and rheumatic disease severity, only 10% of rheumatology visits document cessation counseling. After implementing a rheumatology clinic protocol that increased tobacco quitline referrals 20-fold, current objectives were to 1) examine patients' barriers and facilitators to smoking cessation based on prior rheumatology experiences, 2) solicit reactions to the new cessation protocol, and 3) identify patient-centered outcomes or "signs of cessation progress" following improved care.

Methods: We recruited 19 patients who smoke-12 with rheumatoid arthritis (RA) and 7 with systemic lupus erythematosus (SLE)-to one of three semi-structured focus groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23858DOI Listing
February 2019

Neutrophil-derived lactoferrin induces the inflammatory responses of rheumatoid arthritis synovial fibroblasts via Toll-like receptor 4.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Rheumatology, Infectious Diseases, and Laboratory Medicine, Faculty of Medicine, University of Miyazaki, Japan.

Objectives: Damage-associated molecular patterns (DAMPs) are proposed to drive aberrant stimulation of Toll-like receptors (TLRs) in rheumatoid arthritis (RA) inflamed joints. In the current study we investigated the role of the neutrophil-derived lactoferrin (LTF), as an endogenous ligand for TLR4 in the inflammatory response of RA synovial fibroblasts (RASFs).

Methods: RASFs were stimulated with LTF, and the expressions of inflammatory cytokines in RASFs were measured. Read More

View Article

Download full-text PDF

Source
February 2019

Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis.

Clin Exp Rheumatol 2019 Feb 7. Epub 2019 Feb 7.

Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.

Objectives: To investigate ex-vivo drug-inhibited cytokine production before the start of a biological DMARD (bDMARD) as predictor of treatment response in rheumatoid arthritis (RA).

Methods: In a prospective RA cohort study [BIO-TOP], blood samples were obtained from patients before the start of a bDMARD (abatacept, adalimumab, etanercept, rituximab or tocilizumab). Peripheral blood mononuclear cells were pre-incubated for 1 hour with the therapeutic in-vivo concentration of the bDMARD and stimulated for 24 hours with heat-killed Candida albicans or Pam3Cys. Read More

View Article

Download full-text PDF

Source
February 2019

Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Rheumatology, Department of Medicine, University of Ulsan, College of Medicine, Asan Medical Centre, Seoul, Korea.

Objectives: To investigate the effect of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis.

Methods: Patients with RA who were newly diagnosed with osteoporosis (T-score ≤ -2.5) between 2010 and 2017 were included. Read More

View Article

Download full-text PDF

Source
February 2019

IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Rheumatology and Immunology, the First Affiliated Hospital of China Medical University, Shenyang, China.

Objectives: Angiogenesis in bone and osteogenesis appear to be closely linked, suggesting the existence of molecular crosstalk between pro-angiogenic molecules and osteoblasts. The pro-angiogenic molecules vascular endothelial growth factor (VEGF) with its receptors Flt-1, Flk-1 and fibroblast growth factor (FGF)-2 play a crucial role in born formation, an early and critical event in the pathogenesis of rheumatoid arthritis (RA). Interleukin (IL)-35 is demonstrated to be an anti-inflammatory cytokine in RA. Read More

View Article

Download full-text PDF

Source
February 2019

The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Klinikum der Universität München, Munich, Germany.

Numerous cytokines have been implicated in the pathogenesis of inflammatory diseases, and their dysregulation is a main feature of rheumatoid arthritis (RA). Cytokines stimulate signal transduction through several intracellular pathways, including Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathways, leading to changes in cell activation, proliferation and survival. Consequently, agents that selectively target elements of the JAK/STAT pathways have received significant attention in recent years as potential new treatments for the disease. Read More

View Article

Download full-text PDF

Source
February 2019

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Int J Rheum Dis 2019 Feb 14. Epub 2019 Feb 14.

Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.

Objectives: To evaluate the transition from reference infliximab Remicade to biosimilar Remsima in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

Methods: Patients were informed through a letter about the transition to a biosimilar and were subsequently contacted for possible additional questions and whether they agreed upon the transition. Once agreed, Remsima was administered at the same dosage and interval as previous treatment with Remicade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13512DOI Listing
February 2019

Degradation Characteristics of a Novel PAF Receptor Antagonist, SY0916, in Aqueous Solution.

J Anal Methods Chem 2019 14;2019:8789470. Epub 2019 Jan 14.

Institute of Material Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

SY0916 has been proven to be a potent treatment agent against rheumatoid arthritis in preclinical studies and has been shown to be safe in phase I clinical trials. However, SY0916 is unstable in water, which is frequently used in pharmaceutical development processes. The degradation behaviour and stability of SY0916 in aqueous solutions were investigated at different pH levels, periods of time, and temperatures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8789470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350595PMC
January 2019

Baricitinib for rheumatoid arthritis.

Authors:

Aust Prescr 2019 Feb 13;42(1):34-35. Epub 2018 Dec 13.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18773/austprescr.2018.070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370601PMC
February 2019

IL-17 and limits of success.

Cell Immunol 2018 Sep 17. Epub 2018 Sep 17.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States. Electronic address:

Interleukin-17 (IL-17) is a potent proinflammatory cytokine that protects a host against fungal and extracellular bacterial infections. On the other hand, excessive or dysregulated production of IL-17 underlines susceptibility to autoimmune disease. Consequently, blocking IL-17 has become an effective strategy for modulating several autoimmune diseases, including multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2018.09.001DOI Listing
September 2018

What is the additional value of MRI of the foot to the hand in undifferentiated arthritis to predict rheumatoid arthritis development?

Arthritis Res Ther 2019 Feb 14;21(1):56. Epub 2019 Feb 14.

Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.

Background: MRI-detected subclinical joint inflammation in the hand joints of patients with undifferentiated arthritis (UA) predicts progression to rheumatoid arthritis (RA). It is unknown if adding MRI of the foot increases predictive accuracy compared to the hand alone.

Methods: 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1845-7DOI Listing
February 2019

Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.

Arthritis Res Ther 2019 Feb 14;21(1):58. Epub 2019 Feb 14.

Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Background: Biomarkers have been actively investigated to supplement functional and imaging modalities to predict the severity, therapeutic responsiveness, and progression of connective tissue disease-associated interstitial lung disease (CTD-ILD). This study aimed to evaluate Krebs von den Lungen 6 (KL-6) as a potential biomarker reflecting the severity of CTD-ILD as assessed through computed tomography (CT) and pulmonary function test (PFT) parameters.

Methods: This retrospective study included 549 Korean patients with rheumatoid arthritis, systemic sclerosis, inflammatory myositis, and other CTDs with or without concurrent ILD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1835-9DOI Listing
February 2019

Do musculoskeletal ultrasound and magnetic resonance imaging identify synovitis and tenosynovitis at the same joints and tendons? A comparative study in early inflammatory arthritis and clinically suspect arthralgia.

Arthritis Res Ther 2019 Feb 14;21(1):59. Epub 2019 Feb 14.

Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.

Objective: Ultrasound (US) and magnetic resonance imaging (MRI) are recommended in the diagnostic process of rheumatoid arthritis. Research on its comparability in early disease phases is scarce. Therefore, we compared synovitis and tenosynovitis detected by US and MRI on joint/tendon level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1824-zDOI Listing
February 2019

Porphyromonas gingivalis promotes the motility of esophageal squamous cell carcinoma by activating NF-κB signaling pathway.

Microbes Infect 2019 Feb 11. Epub 2019 Feb 11.

Guangdong Provincial Institute of Geriatrics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China; Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

Esophageal carcinoma, with a increasing incidence, is one of the most aggressive carcinomas in gastrointestinal tract. Epidemiologic studies demonstrate an association of oral pathogens with multiple diseases, including rheumatoid arthritis, cardiovascular diseases, diabetes, and gastrointestinal malignancies. Nevertheless, a causal relationship between oral pathogens and esophageal squamous cell carcinoma (ESCC) has not been elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.micinf.2019.01.005DOI Listing
February 2019

Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.

J Clin Pharm Ther 2019 Feb 14. Epub 2019 Feb 14.

Turkish Medicines and Medical Devices Agency, Ministry of Health, Ankara, Turkey.

What Is Known And Objective: Anti-tumour necrosis factor-alpha (anti-TNF-α) therapy is known to raise the risk of granulomatous infections, leading to development of risk management strategies at national or global level. This study aimed to determine the relative risk (RR) of tuberculosis (TB) due to anti-TNF-α usage in patients with rheumatologic diseases (RDs) in a nationwide basis.

Method: This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without anti-TNF-α agents, as registered in the national prescription information system between years 2013 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.12814DOI Listing
February 2019

Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study.

PLoS One 2019 14;14(2):e0212460. Epub 2019 Feb 14.

Department of Pharmacy, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.

In recent years, low dose naltrexone (LDN) has been used as an off-label therapy for several chronic diseases. Results from small laboratory and clinical studies indicate some beneficial effects of LDN in autoimmune diseases, but clinical research on LDN in rheumatic disease is limited. Using a pharmacoepidemiological approach, we wanted to test the hypothesis that starting LDN leads to reduced dispensing of medicines used in the treatment of rheumatic disease. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212460PLOS
February 2019
1 Read